VRFs are associated with lower FDG-PET (Langbaum et al., 2012), more cerebrovascular disease (CVD) (Bangen et al., 2015), higher cerebral Aβ burden (Langbaum et al., 2012; Gottesman et al., 2017), and higher tau burden (Langbaum et al., 2012; Gottesman et al., 2017), and they act synergistically with Aβ burden to promote cognitive decline (Rabin et al., 2018). The gene discussed is MAPT; the disease is Mental deterioration.